0001004878-17-000204.txt : 20170831 0001004878-17-000204.hdr.sgml : 20170831 20170831173043 ACCESSION NUMBER: 0001004878-17-000204 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170831 DATE AS OF CHANGE: 20170831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-205444 FILM NUMBER: 171064044 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 424B3 1 prospsuppddee8-17.txt PRO SUPP SERIES DD & EE WARRANTS PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) (To Prospectus Supplement Registration No. 333-205444 dated December 8, 2016) CEL-SCI CORPORATION Series DD and Series EE Warrants On August 29, 2017 the Company extended the expiration date of its Series DD and Series EE warrants until the close of business on December 1, 2017. The Series DD and Series EE warrants were issued as part of a financing on December 8, 2016. As a result of the reverse stock split approved by the Company's shareholders and adopted by the Company's directors: o the holders of the Series DD warrants are entitled to purchase 1,360,960 shares of the Company's common stock at an exercise price of $4.50 per share; and o the holders of the Series EE warrants are entitled to purchase 1,360,960 shares of the Company's common stock at an exercise price of $4.50 per share. Prospectus Supplement dated August 29, 2017